Business
Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
Patient Access Initiative Addresses €1 Billion Annual Market in Germany BERKELEY, US and MAINZ, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV
About this update from Quantum Cyber N.v.
[{"type":"text","content":"Patient Access Initiative Addresses €1 Billion Annual Market in Germany\nBERKELEY, US and MAINZ, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the launch of a corporate health program in Germany for ColoAlert, its highly efficacious and easy-to-use screening test for colorectal cancer (CRC) being commercialized across Europe and in select international territories. As a start, ColoAlert has been integrated into BGM (“betriebliches Gesundheitsmanagement”), a corporate health network providing services to employees at forty-eight of the fifty largest companies in Germany1. “The corporate health market is a fundamental component of our commercial strategy, and it’s a pleasure to commence this initiative with leading German based companies who are committed to the health and well-being of their employees,“ commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Providing access to ColoAlert is an important option for employees given CRC is the second most lethal cancer in Europe and is most treatable with early detection.” Through corporate health management programs such as the BGM network, best-in-class companies offer employees healthcare services ranging from gym memberships to diabetes management to counseling, all to better their health. This investment improves employee satisfaction and performance, which in turn contributes to the organization’s long-term success. Mainz Biomed’s integration into the BGM network includes the launch of an online portal through which employees can register to be sent the ColoAlert test. Once the sample is received and processed, confidential test results are sent back to the employee through the portal, along with an explanation of the results. If an employee has approved for their physician to also be notified, then the doctor can follow up with the patient accordingly. Mainz Biomed provides education for both the employee and physician regarding the ColoAlert results and CRC, as well as recommendations for next steps. About ColoAlertColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy (Dollinger MM et al., 2018). The test...